GlassScriptPhysician profile
Joel M Johnson
NPI 1619902442
$1,443.83
in general payments reported to CMS, 2019-2025
27 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $94.88 · 2021: $111 · 2022: $142 · 2023: $221 · 2024: $336 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.22 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $152.71 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $143.51 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Glaxosmithkline, LLC. | $116.35 | 2021-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Novo Nordisk INC | $103.68 | 2021-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $102.37 | 2019-2024 | Watchman Flx |
| Amgen INC. | $88.93 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $79.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $64.10 | 2019-2024 | Veozah |
| Abbott Laboratories | $45.89 | 2021-2025 | Eterna |
| Genentech USA, INC. | $42.72 | 2019-2021 | |
| Vbi Vaccine (Delaware) INC. | $32.62 | 2022 | |
| Arbor Pharmaceuticals, INC. | $31.22 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $28.70 | 2025 | Gemtesa |
| Ars Pharmaceuticals Operations, INC. | $26.27 | 2025 | Neffy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.50 | 2023 | |
| Lilly USA, LLC | $24.31 | 2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $21.18 | 2024 | Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $18.83 | 2022 | |
| Eisai INC. | $17.21 | 2021 | |
| Pbg Puerto Rico LLC | $16.83 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.76 | 2022 | |
| Horizon Therapeutics Plc | $16.49 | 2023 | Krystexxa |
| Lucid Diagnostics INC. | $15.19 | 2025 | |
| Optinose US, INC. | $14.15 | 2020 | |
| Gilead Sciences, INC. | $13.00 | 2019 | |
| Allergan, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.